{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:25:19Z","timestamp":1787034319485,"version":"build-2736575974"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Axillary management in breast cancer has shifted significantly with the increasing use of neoadjuvant chemotherapy (NACT), particularly in biologically aggressive subtypes such as HER2-positive breast cancer and triple-negative breast cancer (TNBC). Intraoperative frozen section evaluation of sentinel lymph nodes (SLNs) has traditionally guided axillary dissection, but recent evidence suggests that omitting axillary dissection in patients with minimal or no residual disease provides comparable local control when combined with axillary radiotherapy. This study aimed to evaluate whether intraoperative frozen section or paraffin section assessment affects axillary management in patients who are clinically node negative (cN0) before NACT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 83 patients with HER2-positive breast cancer or TNBC treated between 2023 and 2025. All patients were clinically and radiologically node negative prior to NACT. SLN biopsy was performed using isosulfan blue, dual technique, indocyanine green, or combinations. Intraoperative frozen section analysis was performed in 59 patients, while paraffin section was used in 24 patients. Clinicopathological features, SLN positivity, pathological response rates, axillary recurrence, and surgical decisions were compared. Statistical analyses were performed using SPSS 18.0, with p &amp;lt; 0.05 considered significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age was 48.2 years. A pathological complete response (pCR) was achieved in 71% of patients, of whom 96.6% had negative SLNs. Among patients with partial response, 75% had negative SLNs. SLN positivity was observed in 8.5% (n = 5) of patients in the frozen section group and 12.5% (n = 3) in the paraffin section group. Axillary dissection was performed only in the frozen section group. No axillary recurrences occurred in either group after a median follow-up of 22 months. Paraffin section evaluation did not result in delayed treatment or increased recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In HER2-positive and TNBC patients with cN0 status before NACT and a good pathological response, frozen section analysis of SLNs does not influence surgical decision-making. Paraffin section evaluation may represent a feasible alternative in carefully selected patients with HER2-positive breast cancer or TNBC who achieve an excellent response to neoadjuvant chemotherapy. However, these findings should be interpreted cautiously given the retrospective design, small sample size, and relatively short follow-up, and require validation in larger prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1848864","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:37:30Z","timestamp":1787031450000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Omission of frozen section in sentinel lymph node biopsy after neoadjuvant chemotherapy in cN0 HER2-positive and TNBC"],"prefix":"10.3389","volume":"16","author":[{"given":"Ferit","family":"Aydin","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Ankara Etlik City Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazim Caglar","family":"Ozcelik","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Ankara Etlik City Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Tunc","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Ankara Etlik City Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Aslan","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Ankara Etlik City Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut Onur","family":"Kulturoglu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Ankara Etlik City Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Furkan","family":"Sagdic","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Ankara Etlik City Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Aksel","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Ankara Etlik City Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutf\u0131","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Ankara Etlik City Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12957-024-03547-7","article-title":"Axillary lymph node dissection is not required for breast cancer patients with minimal axillary residual disease after neoadjuvant chemotherapy","volume":"22","author":"Muslumanoglu","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.21203\/rs.3.rs-6129601\/v1","article-title":"Intraoperative frozen section analysis can be omitted in early breast cancer without significantly elevating reoperation rates","volume":"25","author":"Aydin","year":"2025","journal-title":"BMC Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.01052","article-title":"Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05\/ICARO Study","volume":"43","author":"Montagna","year":"2025","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35610","article-title":"Combined analysis of the MF18-02\/MF18-03 NEO-SENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in breast cancer patients with good response to neoadjuvant chemotherapy when radiotherapy is provided","volume":"131","author":"Muslumanoglu","year":"2024","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199907000-00011","article-title":"Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy","volume":"230","author":"Kuerer","year":"1999","journal-title":"Ann Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4935","article-title":"Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy","volume":"2","author":"Mougalian","year":"2016","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25152","article-title":"Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer","volume":"116","author":"Dominici","year":"2010","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.0562","article-title":"Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery","volume":"152","author":"Tadros","year":"2017","journal-title":"JAMA Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.2696","article-title":"Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy","volume":"153","author":"Barron","year":"2018","journal-title":"JAMA Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00423-025-03767-9","article-title":"Changing practice patterns in axillary management for patients with node-positive breast cancer towards increased use of sentinel lymph node biopsy alone after neoadjuvant chemotherapy: results of a survey (MF17-01) among Turkish surgeons","volume":"410","author":"Cabioglu","year":"2025","journal-title":"Langenbecks Arch Surg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1848864\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:37:30Z","timestamp":1787031450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1848864\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":14,"alternative-id":["10.3389\/fonc.2026.1848864"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1848864","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1848864"}}